GARDASIL 9

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug GARDASIL 9 contains a combination of these active pharmaceutical ingredients (APIs):

1 L1 protein of human papillomavirus type 6 UNII 61746O90DY - HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 6

2 L1 protein of human papillomavirus type 11 UNII Z845VHQ61P - HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 11

3 L1 protein of human papillomavirus type 16 UNII 6LTE2DNX63 - HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 16

4 L1 protein of human papillomavirus type 18 UNII J2D279PEM5 - HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 18

5 L1 protein of human papillomavirus type 31 UNII 53JIL371NS - HUMAN PAPILLOMAVIRUS TYPE 31 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 31

6 L1 protein of human papillomavirus type 33 UNII 759RAC446C - HUMAN PAPILLOMAVIRUS TYPE 33 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 33

7 L1 protein of human papillomavirus type 45 UNII 68S8VCN34F - HUMAN PAPILLOMAVIRUS TYPE 45 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 45

8 L1 protein of human papillomavirus type 52 UNII 55644W68FD - HUMAN PAPILLOMAVIRUS TYPE 52 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 52

9 L1 protein of human papillomavirus type 58 UNII 94Y15HP7LF - HUMAN PAPILLOMAVIRUS TYPE 58 L1 CAPSID PROTEIN ANTIGEN

Read about L1 protein of human papillomavirus type 58

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
GARDASIL 9 Suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BM03		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BM Papillomavirus vaccines
Discover more medicines within J07BM03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 525518080020601, 525518080020701
Country: CA	Health Products and Food Branch	Identifier(s): 02437058
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 45-MBE-0116
Country: EE	Ravimiamet	Identifier(s): 1687372, 1687383, 1687394
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1151007002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 581896
Country: FR	Base de données publique des médicaments	Identifier(s): 65017887
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 334932
Country: HK	Department of Health Drug Office	Identifier(s): 64239, 66391
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8254
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1077100, 1077101, 1077102, 1088656
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 196959
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 17829
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100347350
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68784001, W68784002
Country: SG	Health Sciences Authority	Identifier(s): 15141P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699636951262
Country: US	FDA, National Drug Code	Identifier(s): 0006-4119, 0006-4121
Country: ZA	Health Products Regulatory Authority	Identifier(s): 51/30.1/0264